Avibactam

In response to the clinical treatment dilemma of multidrug-resistant Gram-negative bacterial infections, the iteration of β-lactamase inhibitors is an important breakthrough direction. Avibactam is a new type of non-β-lactam β-lactamase inhibitor, which can reversibly inhibit Class A, Class C and some Class D β-lactamases through covalent binding. When used in combination with antibiotics such as ceftazidime and meropenem, it can effectively restore the susceptibility of pathogenic bacteria to drugs. At present, its compound preparations are mainly used to treat adult patients with complicated intra-abdominal infections, complicated urinary tract infections, hospital-acquired pneumonia, etc., and are especially suitable for the treatment of carbapenem-resistant bacterial infections, providing an important medication guarantee for ICU, elderly and immunocompromised populations at high risk of drug-resistant bacterial infections.

The global market size of avibactam-related preparations had exceeded 4.2 billion US dollars in 2023, with a compound annual growth rate of around 18% in the past 5 years. The core growth driver comes from the continuous rise in the resistance rate of Gram-negative bacteria worldwide. In terms of the domestic market, the original research product has achieved rapid volume growth after entering the medical insurance catalog in 2019. At present, 5 domestic pharmaceutical companies have obtained approval for the marketing of generic avibactam compound preparations. In the 2024 provincial-level centralized drug procurement, the average price reduction of avibactam compound preparations reached 56%. The demand for upstream API has continued to expand along with the increase in the penetration rate of generic drugs. At present, domestic API manufacturers are mainly local pharmaceutical companies, and the overall supply pattern is relatively stable.

CATO can provide a full set of impurity reference standards for avibactam API. All products meet the quality requirements of multiple regulatory systems such as Chinese Pharmacopoeia and FDA. Core specifications are kept in stock, which can quickly respond to the demands of API manufacturers and R&D institutions related to impurity research and quality control, effectively shortening the cycle of declaration and quality verification.